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The SPOP E3 ubiquitin ligase gene is frequently
mutated in human prostate cancers. Here, we
demonstrate that SPOP recognizes a Ser/Thr-rich
degron in the hinge domain of androgen receptor
(AR) and inducesdegradationof full-lengthARand in-
hibition of AR-mediated gene transcription and pros-
tate cancer cell growth. AR splicing variants, most
of which lack the hinge domain, escape SPOP-
mediated degradation. Prostate-cancer-associated
mutants of SPOP cannot bind to and promote
AR destruction. Furthermore, androgens antagonize
SPOP-mediated degradation of AR, whereas antian-
drogens promote this process. This study identifies
AR as a bona fide substrate of SPOP and elucidates
a role of SPOP mutations in prostate cancer, thus
implying the importance of this pathway in resistance
to antiandrogen therapy of prostate cancer.INTRODUCTION
Prostate cancer is one of the most common malignancies, with
over 913,000 new cases and over 261,000 deaths worldwide
each year (Ferlay et al., 2010). Although androgen deprivation
therapies are initially effective in approximately 90% of prostate
cancer patients, the disease inevitably recurs as lethal castra-
tion-resistant prostate cancer (CRPC).
Androgen receptor (AR) is a pivotal transcription factor that is
essential for normal prostate cell growth and survival. AR is also
important for initiation and progression of prostate cancer. The
role of AR in prostate cancer initiation is accentuated by the
seminal discovery that the oncogenic ETS family transcription
factors, such as ERG and ETV1, are translocated to the loci of
androgen regulated genes including TMPRSS2 in approximatelyC50% of all human prostate cancers (Kumar-Sinha et al., 2008;
Tomlins et al., 2005). Development of CRPC is considered to
be causally related to a persistent activation of AR by a number
of mechanisms, including, but not limited to, AR amplification or
overexpression; gain-of-function mutations that allow AR to be
activated by other steroids or antiandrogens; ligand-indepen-
dent activation of the AR by cytokine/growth factor-dependent
pathways; overexpression of AR coactivators; intracrine sig-
naling by increased intratumoral androgen synthesis; and ex-
pression of constitutively active splicing variants of AR (Cai
et al., 2011; Chen et al., 2004; Dehm and Tindall, 2011; Gross-
mann et al., 2001; Scher and Sawyers, 2005). The importance
of AR reactivation during castration-resistant progression of
prostate cancer has been clinically confirmed by the effective
treatment of CRPC by second-generation androgen-AR axis in-
hibitors including abiraterone and enzalutamide (MDV3100) (de
Bono et al., 2011; Scher et al., 2012).
Covalent attachment of ubiquitin via enzyme cascades (E1,
E2s, and E3s) constitutes a fundamental mechanism that pro-
motes either protein turnover or signaling transduction. Ubiquitin
ligases, or E3s, selectively bind to and target substrates for ubiq-
uitination and subsequent proteasome degradation. The largest
E3 ligase subfamily consists of Cullin-RING ligases (CRLs),
which are multisubunit enzymes, consisting of hundreds of
distinct CRL complexes with the capacity to recruit numerous
substrates (Petroski and Deshaies, 2005). Human cells express
seven different CULLINs (CUL1, 2, 3, 4A, 4B, 5, and 7), each of
which nucleates a multisubunit E3 ubiquitin ligase complex (Pet-
roski and Deshaies, 2005). The CRL3 complex is composed of
the scaffold CUL3 and RING protein RBX1, in combination with
a BTB (Bric-a-brac/Tramtrack/Broad complex) domain protein
that acts as an adaptor for substrate binding. The human
genome encodesmore than 180 BTB proteins. One well-charac-
terized BTB protein is SPOP, which contains a substrate-binding
MATH domain at the N-terminal and a CUL3-binding BTB
domain at the C-terminal. SPOP has been linked to ubiquitina-
tion of several substrates in Drosophila and human, such asell Reports 6, 657–669, February 27, 2014 ª2014 The Authors 657
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Puc, Ci/Gli, MacroH2A, Daxx, and SRC-3 (Herna´ndez-Mun˜oz
et al., 2005; Kwon et al., 2006; Li et al., 2011; Liu et al., 2009;
Zhang et al., 2006).
Mounting evidence indicates that dysregulation of the ubiqui-
tin-proteasome pathway is involved in cancer pathogenesis.
Systematic whole-genome or exome sequencing of prostate
tumors has led to the identification of frequent somaticmutations
in SPOP (Barbieri et al., 2012; Berger et al., 2011; Grasso et al.,
2012; Kan et al., 2010). Interestingly, all SPOP mutations
described thus far affect evolutionarily conserved residues in
the structurally defined substrate-binding MATH domain. Impor-
tantly, prostate tumors that contain mutated SPOP almost
completely lack mutations in PTEN and TP53 tumor suppres-
sors, suggesting a new molecular subtype of prostate cancer
(Barbieri et al., 2012). In addition to mutations, SPOP protein
expression is often downregulated in prostate tumors (Kim
et al., 2013). However, how this contributes to prostate cancer
pathogenesis and progression remains to be defined. In this
study, we identified AR as a degradation substrate of SPOP in
prostate cancer cells.
RESULTS
AR Is a Bona Fide Substrate of the SPOP-CUL3-RBX1 E3
Ligase Complex
All SPOPmutations detected thus far in prostate cancer occur in
the structurally defined substrate-binding motif (Barbieri et al.,
2012; Zhuang et al., 2009), suggesting that the pathophysiology
of SPOP mutations in prostate cancer is relevant to its func-
tion in substrate binding and degradation. A SPOP-binding
consensus motif F-p-S-S/T-S/T (F: nonpolar residues, p: polar
residues) has been identified in several SPOP substrates
including Puc, MacroH2A, Ci/Gli, and Daxx (Herna´ndez-Mun˜oz
et al., 2005; Kwon et al., 2006; Liu et al., 2009; Zhang et al.,
2006). We performed a protein motif search and discoveredFigure 1. The SPOP-CUL3-RBX1 Complex Targets AR for Ubiquitinatio
(A) Comparison of putative SPOP binding sites in AR with the SPOP-binding con
(B) Ectopically expressed SPOP promotes exogenous AR protein degradation.
western blot (WB). ERK2, a loading control.
(C) SPOP regulates AR protein levels through the proteasome pathway. 293T cell
After 16 hr, cells were treated with 20 mM MG132 for 8 hr and harvested for WB.
(D) SPOP regulates endogenous AR protein levels. LNCaP cells were transfected w
(E) Knockdown of SPOP increases endogenous AR protein levels. LNCaP andC4-
After 48 hr, cells were harvested for WB.
(F and G) SPOP knockdown prolongs AR protein half-life. LNCaP cells were trans
50 mg/ml cycloheximide (CHX). At different time points, cells were harvested for W
ERK2 (loading control) first and then to the value at the 0 hr time point (G). A sim
(H) The BTB domain in SPOP is essential for SPOP-mediated degradation of AR.W
DBTB plasmids into 293T cells for 24 hr, followed by WB.
(I) Knockdown of RBX1 or CUL3 increases endogenous AR protein levels. LNCaP
followed by WB.
(J) SPOP promotes AR polyubiquitination in vivo. 293T cells were transfected with
Immunoprecipitated AR proteins were analyzed by WB for ubiquitination.
(K) Knockdown of SPOP decreases ubiquitination of endogenous AR. LNCaP ce
treatment with 20 mM MG132 for 8 hr, and then the same procedure was perform
(L) Quantitative RT-PCR measurement of the mRNA level of SPOP, AR, and two
mRNA level of GAPDH was used for normalization. All data shown are mean val
(M and N) SPOP inhibits prostate cancer cell growth via regulation of AR. C4-2 ce
small hairpin RNAs. Forty-eight hours after infection, cells were harvested for WB (
are mean values ± SD (error bar) from six replicates. p < 0.01.
Cthat AR harbors one perfectly matched (645ASSTT649) and one
imperfectly matched (203EGSSS207) SPOP-binding motif (Fig-
ure 1A). This observation prompted us to investigate whether
SPOP functions as an E3 ubiquitin ligase of AR. As shown in Fig-
ure 1B, coexpression of SPOP, but not the related E3 ligase
SKP2, decreased the ectopically expressed AR protein level in
293T cells. This effect was completely blocked by treatment
with the proteasome inhibitor MG132 (Figure 1C), indicating
that SPOP downregulates AR protein levels via the proteasome
pathway.
Next, we examined the effect of SPOP on degradation of
endogenous AR. Overexpression of SPOP in LNCaP prostate
cancer cells resulted in a marked reduction of the endogenous
level of AR protein in a dose-dependent manner (Figure 1D).
Knockdown of endogenous SPOP by two independent SPOP-
specific small interfering RNAs (siRNAs) increased AR protein
levels in both LNCaP and C4-2 prostate cancer cells (Figure 1E).
Furthermore, knockdown of SPOP markedly prolonged the
half-life of endogenous AR protein in LNCaP cells (Figures 1F
and 1G).
SPOP is a substrate-binding subunit of the SPOP-CUL3-RBX1
E3 ligase complex. The C-terminal BTB domain of SPOP is
essential for its interaction with the scaffold protein CULLIN3
(CUL3). The BTB deletion mutant of SPOP (SPOP-DBTB) cannot
form a complex with CUL3 and RBX1 to function as an enzymat-
ically active E3 ligase (Weber et al., 2005). As shown in Figure 1H,
only wild-type SPOP, but not the SPOP-DBTBmutant, promoted
AR degradation, indicating that the BTB domain and the CUL3-
RBX1 complex are required for SPOP-mediated degradation of
AR. Next, we sought to determine whether other subunits of
the SPOP-CUL3-RBX1 E3 ligase complex are required for AR
degradation. We knocked down RBX1 or CUL3 by two indepen-
dent gene-specific siRNAs and examined AR protein levels in
LNCaP cells. As shown in Figure 1I, knockdown of either RBX1
or CUL3 resulted in a dramatic increase in AR protein levels.n and Degradation
sensus motif defined in the known SPOP substrates.
293T cells were transfected with indicated constructs for 24 hr followed by
s were transfected with 4 mg pCMV5-AR and 0, 2, or 4 mgMyc-SPOP plasmids.
ith 0, 2, or 4 mgHA-SPOPplasmid for 24 hr before cells were harvested forWB.
2 cells were transfected with control or two independent SPOP-specific siRNA.
fected with control or SPOP-specific siRNA. After 48 hr, cells were treated with
B (F). At each time point, the intensity of AR was normalized to the intensity of
ilar result was obtained in two independent experiments.
e transfected 4 mg pCMV5-AR and 0, 2, or 6 mgMyc-SPOP-WT orMyc-SPOP-
cells were transfected with control siRNA or siRNAs for RBX1 or CUL3 for 48 hr
indicated plasmids for 16 hr followed by treatment with 20 mMMG132 for 8 hr.
lls were transfected with indicated plasmids and siRNAs for 40 hr followed by
ed as shown in (J).
AR target genes (PSA and TMPRSS2) in SPOP-knockdown LNCaP cells. The
ues ± SD (error bar) from three independent experiments. p < 0.01.
lls were infected with lentivirus expressing control or SPOP and/or AR-specific
M) or cultured in androgen-depletedmedium for MTS assay (N). All data shown
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Figure 2. SPOP Interacts with AR In Vitro and In Vivo
(A and B) Ectopically expressed SPOP and AR proteins interact with each other. 293T cells were transfected with indicated plasmids for 16 hr followed by
treatment with 20 mM MG132 for 8 hr and coIP with anti-HA (A) or anti-AR (B) and WB.
(C) Endogenous SPOP and ARproteins interact with each other in LNCaP cells. After treatment with 20 mMMG132 for 8 hr, cell lysates were prepared for coIPwith
AR antibody and WB. SKP2 was included as a negative control.
(D) Schematic diagram of three GST-AR recombinant proteins. NTD, NH2-terminal domain; DBD, DNA binding domain; LBD, ligand binding domain.
(E) SPOP binds to the central part of AR including DBD and the hinge domain. Bacterially expressed GST fusion proteins of NTD, LBD, and DBD plus the hinge
domain were incubated with cell lysates of 293T cells transfected with HA-SPOP and subjected to GST pull-down assay. Bound HA-SPOP was detected by WB
with HA antibody, and GST fusion proteins were detected by GelCode blue staining.These data suggest that the E3 ligase function of SPOP is
required for its destruction of AR.
To determine whether SPOP regulates AR polyubiquitination,
HA-Ub and pCMV5-AR were coexpressed in 293T cells with
different doses of wild-type SPOP (SPOP WT) or enzymatic
dead mutant (SPOP-DBTB). AR protein was robustly polyubi-
quitinated by coexpression of SPOP WT, but not SPOP-
DBTB, in a dose-dependent manner (Figure 1J). Accordingly,
knockdown of endogenous SPOP in LNCaP cells decreased
the polyubiquitination of endogenous AR (Figure 1K). These
data support the concept that the SPOP regulates AR stability
through ubiquitin-dependent proteasome degradation in pros-
tate cancer cells.
Consistent with the finding that SPOP knockdown increased
AR protein levels (Figure 1E), it also increased the transcriptional
activity of AR by upregulating mRNA expression of PSA and
TMPRSS2, two well-studied AR transcriptional targets (Fig-
ure 1L). In contrast, SPOP knockdown had no effect on expres-
sion of ARmRNA itself, further indicating that the effect of SPOP
on AR is not mediated by regulation of AR expression at the
mRNA level. In agreement with a previous report that overex-
pression of wild-type SPOP inhibits the growth of LNCaP-Abl
CRPC cells (Geng et al., 2013), knockdown of endogenous
SPOP increased the growth of C4-2 CRPC cells (Figures 1M
and 1N). Importantly, this effect was almost completely abro-
gated by concomitant knockdown of AR (Figure 1N). Moreover,
AR knockdown alone markedly inhibited C4-2 cell growth (Fig-660 Cell Reports 6, 657–669, February 27, 2014 ª2014 The Authorsure 1N), which is in agreement with a previous report (Zegarra-
Moro et al., 2002). Together, these findings suggest that SPOP
promotes AR protein ubiquitination and proteasome degrada-
tion and inhibits prostate cancer cell growth in an AR-dependent
manner.
SPOP Interacts with AR In Vitro and In Vivo
Because substrate binding is a key event for E3 ligase-mediated
ubiquitination and subsequent proteasome degradation, we
examined the binding of AR by SPOP using coimmunoprecipita-
tion (coIP) assay. As shown in Figure 2A, ectopically expressed
AR protein was coimmunoprecipitated by HA-SPOP. A similar
result was obtained in a reciprocal coIP experiment using AR
antibody (Figure 2B). Importantly, endogenous SPOP and AR
proteins were present in the same complex coimmunoprecipi-
tated by AR antibody in LNCaP cells (Figure 2C). Next, we sought
to determine which domain(s) of AR is required for SPOP bind-
ing. AR has four well-defined functional domains including the
N-terminal domain (NTD), DNA binding domain (DBD), hinge
domain, and ligand binding domain (LBD) (Figure 2D). We puri-
fied glutathione S-transferase (GST) recombinant proteins for
three truncation mutants of AR: NTD (amino acids 1–565), DBD
plus hinge domain (amino acids 505–676), and LBD (amino acids
659–919). The GST pull-down assay demonstrated that SPOP
binds specifically to the central region of AR including the DBD
and hinge domain, but not the AR NTD and LBD, or GST alone
(Figure 2E).
Figure 3. The 645ASSTT649 Motif in AR Is a Degron Recognized by SPOP
(A) Diagram showing two putative SPOP-binding motifs located in AR NTD and the hinge domain, respectively.
(B) The 645ASSTT649 motif is required for AR binding to SPOP. 293T cells were transfected with plasmids for Myc-SPOP and wild-type (WT) and three deletion
mutants of AR (DEGSSS,DASSTT, and double deletion 2D). After 16 hr, cells were treatedwith 20 mMMG132 for 8 hr followed by coIP withMyc antibody andWB.
(C) The 645ASSTT649 motif is required for AR degradation by SPOP. 293T cells were transfected with indicated plasmids for 24 hr followed by WB.
(D) S647 and T648 residues in the 645ASSTT649 motif are critical for SPOP-induced degradation of AR. 293T cells were transfected with the indicated plasmids for
24 hr followed by WB. The density of AR was determined by normalizing to ERK2 (loading control) first and then to the normalized value in Myc-SPOP-
untransfected cells.
(E) The 645ASSTT649 motif is essential for SPOP-induced AR polyubiquitination. 293T cells were transfected with the indicated plasmids for 16 hr followed by
treatment with 20 mM MG132 for 8 hr, IP, and WB.
(F and G) Deletion of the 645ASSTT649 motif prolongs the half-life of AR protein. ARWT or AR DASSTTmutant was transfected into 293T cells for 24 hr followed by
treatment with 50 mg/ml cycloheximide (CHX). At various time points, cells were harvested for WB (F). At each time point, the intensity of AR was normalized to the
intensity of ERK2 first and then to the value at the 0 hr time point (G). A similar result was obtained in two independent experiments.The 645ASSTT649 Motif in the AR hinge Domain Is
Required for SPOP-Mediated Degradation of AR
As mentioned above, AR harbors one perfectly matched
(645ASSTT649) and one imperfectly matched (203EGSSS207)CSPOP-bindingmotif (Figure 1A). Because 645ASSTT649 is located
in the SPOP interaction region identified byGST pull-down assay
(Figure 3A), we sought to determine if the 645ASSTT649 motif
plays a role in regulation of SPOP-AR interaction. To this end,ell Reports 6, 657–669, February 27, 2014 ª2014 The Authors 661
Figure 4. Hinge Domain Null AR Splicing Variants Are Resistant to SPOP-Mediated Degradation
(A) Schematic diagram of full-length AR and five AR splicing variants (V2, V5, V7, V4, and v567es). Only full-length AR and v567es contain the 645ASSTT649 motif.
(B) Hinge domain-deficient AR splicing variants lose the capacity of binding to SPOP. 293T cells were transfected with the indicated plasmids for 16 hr followed by
treatment with 20 mM MG132 for 8 hr, coIP, and WB.
(C) Hinge domain null AR splicing variants are resistant to SPOP-promoted degradation. 293T cells were transfectedwith the indicated plasmids for 24 hr followed
by WB.
(legend continued on next page)
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we generated three AR deletion mutants, in which the
203EGSSS207 motif (in the NTD) and the 645ASSTT649 motif
were deleted individually or together. CoIP assays demonstrated
that AR-WT and the DEGSSS mutant were coimmunoprecipi-
tated byMyc-SPOP. In contrast,DASSTT and the doublemutant
(2D) totally lost the SPOP binding capability (Figure 3B). These
data indicate that the perfectly matched SPOP-binding
consensus 645ASSTT649 motif, but not the imperfectly matched
203EGSSS207 motif, is required for SPOP-AR interaction. Next,
we determined if the 645ASSTT649 motif is essential for SPOP-
mediated AR degradation. As shown in Figure 3C, SPOP
efficiently targeted both AR-WT and the DEGSSS mutant for
degradation, but not the DASSTT and 2Dmutants. These results
suggest that the 645ASSTT649 motif located in the hinge domain,
but not the 203EGSSS207motif in NTD, is critical for AR binding by
SPOP and subsequent degradation. To further investigate if the
serine and/or threonine residues in the 645ASSTT649 motif are
crucial for AR binding by SPOP, we generated four point mutants
of AR (S646A, S647A, T648A, and T649A) to determine how
SPOP regulates degradation of these mutants. Overexpression
of SPOP decreased the protein level of AR-WT, S646A, and
T649A mutants, but had little or no effect on the level of AR-
S647A or T648A mutants (Figure 3D). To further determine the
importance of the 645ASSTT649 motif as a degron, AR WT or mu-
tants (DEGSSS, DASSTT, 2D, S647A, and T648A) were cotrans-
fected with or without SPOP in 293T cells. In vivo, ubiquitination
assays demonstrated that SPOP robustly enhanced poly-
ubiquitination of AR-WT and the DEGSSS mutant, but not the
DASSTT and 2D mutants (Figure 3E). Consistent with protein
degradation, S647A and S648A mutations largely diminished
SPOP-induced AR polyubiquitination. Furthermore, the DASSTT
mutation prolonged the half-life of AR protein (Figures 3F and
3G). Thus, these data demonstrate that the 645ASSTT649 motif
functions as an AR degron, which is essential for SPOP binding
and subsequent ubiquitin-dependent degradation of AR, and
that Ser647 and Thr648 residues within this motif are crucial
for this function.
Prostate Cancer-Derived Hinge Domain-Deficient AR
Splicing Variants Escape SPOP-Mediated Proteasome
Degradation
Increasing evidence suggests that C-terminal truncated AR
splice variants play important roles in development of resistance
to antiandrogen therapy in prostate cancer (Li et al., 2013; Sun
et al., 2010). Because a majority of the AR splice variants identi-
fied thus far do not contain the hinge domain (Dehm and Tindall,(D) SPOP binds to endogenous full-length AR but not the variants in 22Rv1 cell
MG132 for 8 hr. Cell lysates were subjected to coP and WB.
(E) Ectopically expressed SPOP differentially targets endogenous full-length AR a
4 mg plasmid for Myc-SPOP-WT or Myc-SPOP-DBTB. After 24 hr, cell lysates w
(F) Knockdown of endogenous SPOP increases protein levels of endogenous full-
SPOP-specific siRNAs for 48 hr followed by WB.
(G) SPOP cannot induce polyubiquitination of hinge domain null AR splicing varian
treatment with 20 mM MG132 for 8 hr, IP, and WB.
(H) Differential effects of SPOP on the transcriptional activity of V7 hinge domain n
luciferase reporter, renilla luciferase reporter, and the indicated plasmids. After
luciferase units (RLU) were determined by first normalizing the firefly units with the
vector (CV). All data shown are mean values ± SD (error bar) from three indepen
C2011), where the SPOP-binding motif is located, we investigated
whether AR splicing variants escape binding by SPOP. We
demonstrated that the v567es variant, which harbors the
SPOP-binding motif 645ASSTT649 (Figure 4A), binds to SPOP in
amanner similar to ARWT (Figure 4B). None of the hinge domain
null AR variants examined, including AR-V2, V5, V7, and V4
(Dehm and Tindall, 2011), was bound by SPOP (Figures 4A
and 4B). Importantly, the steady-state levels of all of the AR
variants examined, except v567es, were unaffected by SPOP
(Figure 4C).
The hinge domain null AR variants V2, V5, V7, and V4 are pre-
dominantly expressed in 22Rv1 prostate cancer cells (Dehm
et al., 2008; Guo et al., 2009; Hu et al., 2009). We demonstrated
that SPOP binds to endogenous full-length AR, but not these
endogenous variants in 22Rv1 cells (Figure 4D). Accordingly,
overexpression of SPOPWT, but not the enzymatic deadmutant
SPOPDBTB, decreased the steady-state level of endogenous
full-length AR in a dose-dependent manner. In contrast, SPOP
WT had little or no effect on the level of endogenous AR variants
in 22Rv1 cells (Figure 4E). Knockdown of endogenous SPOP
increased the steady-state level of endogenous full-length AR
but not the variants in 22Rv1 cells (Figure 4F). Furthermore, over-
expression of SPOP increased polyubiquitination of AR WT and
v567es, but not the hinge domain null variants in 293T cells (Fig-
ure 4G). Finally, we found that the hinge domain null AR variant
AR-V7, but not the hinge domain-containing variant v567es,
was resistant to SPOP-induced inhibition of its transcriptional
activity (Figure 4H). Together, our data demonstrate that hinge
domain null AR splicing variants are resistant to SPOP-mediated
degradation. Thus, constitutive transcriptional activity of these
variants is not affected by SPOP.
Prostate-Cancer-Associated Mutants of SPOP Cannot
Bind to and Promote AR Ubiquitination and Degradation
Recent large-scale somatic mutation studies revealed that
SPOP is one of the most frequently mutated genes in human
prostate tumors (Barbieri et al., 2012; Kan et al., 2010). All the
SPOP mutations found thus far occur in the MATH domain, a
substrate-binding motif (Zhuang et al., 2009). Structural analysis
of these sites has revealed that all the mutated residues are pre-
sent on the surface of the substrate interaction pocket (Barbieri
et al., 2012; Zhuang et al., 2009). We generated a series of
Myc-tagged prostate-cancer-associated mutants of SPOP,
including Y87C, Y87N, F102C, S119N, F125V, W131G, F133L,
and F133V (Barbieri et al., 2012; Kan et al., 2010), and examined
their interaction with AR. We demonstrated that, apart froms. Cells were transfected with Myc-SPOP. After 16 hr, cells were treated with
nd variants for degradation in 22Rv1 cells. Cells were transfected with 0, 2, or
ere prepared for WB.
length AR but not variants in 22Rv1 cells. Cells were transfected with control or
ts. 293T cells were transfected with the indicated plasmids for 16 hr followed by
ull and v567es variants of AR. 293T cells were transfected with PSA-Luc firefly
24 hr, cells were harvested for measurement of luciferase activities. Relative
renilla activity and then normalized to the value of cells transfected with control
dent experiments. p < 0.01.
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Figure 5. Prostate-Cancer-Associated Mutants of SPOP Fail to Promote AR Degradation
(A) Computer modeling of the SPOP MATH domain indicating the positions of the residues mutated in prostate cancer. The side chains of mutated residues are
shown as sticks in red; the substrate is shown as a tube in green; theMATH domain is shown as transparent surface in light gray. The figure ismade using software
vmd-1.9 (http://www.ks.uiuc.edu/Research/vmd/).
(B) Prostate-cancer-associatedmutants of SPOP cannot interact with AR. 293T cells were transfected with the indicated plasmids for 16 hr followed by treatment
with 20 mM MG132 for 8 hr, coIP, and WB.
(C) Prostate-cancer-associatedmutants of SPOP fail to induce degradation of endogenous AR. C4-2 cells were transfected with wild-type (WT) or mutated SPOP
as indicated for 24 hr followed by WB. The density of AR was determined by normalizing to ERK2 (loading control) first and then to the normalized value in Myc-
SPOP-untransfected cells.
(D) Prostate-cancer-associated mutants of SPOP cannot promote AR ubiquitination. 293T cells were transfected with the indicated plasmids. After 16 hr, cells
were treated with MG132 for 8 hr, and cell lysates were prepared for IP and WB.
(legend continued on next page)
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Figure 6. Androgens Attenuate SPOP-
Mediated Degradation of AR
(A) Androgens attenuate the SPOP-AR interaction,
and this effect is blocked by the antiandrogen
enzalutamide. C4-2 cells were cultured in
androgen-depleted medium and treated with the
vehicle ethanol (EtOH), 1 nM mibolerone (Mib),
and/or 10 mM enzalutamide for 24 hr followed by
MG132 treatment for 8 hr, coIP, and WB.
(B) The antiandrogen enzalutamide enhances
SPOP-mediated degradation of endogenous AR.
C4-2 cells were transfected with the indicated
plasmids and cultured in regular (androgen-
containing) medium for 24 hr followed by treat-
ment with mibolerone and/or enzalutamide for
24 hr and WB.
(C) Enzalutamide induces degradation of endog-
enous full-length AR but not variants in 22Rv1
cells. Cells grown in regular (androgen-containing)
medium were pretreated with 10 mg/ml cyclohexi-
mide (CHX) for 4 hr and then treated with different
doses of enzalutamide for 20 hr followed by WB.
(D) Knockdown of SPOP diminishes androgen-
induced increase in AR protein levels. LNCaP cells
were transfected with control or SPOP-specific
siRNA and cultured in androgen-depletedmedium
for 24 hr. Cells were then treated with or without
1 nM mibolerone (Mib) for 24 hr followed by WB.
The density of AR was determined by normalizing
to ERK2 first and then to the normalized value in
mock-treated cells.
(E) Differential effects of androgens on the protein
level of wild-type AR and the SPOP degradation-
resistant mutant. 293T cells were transfected with
the indicated plasmids and cultured in androgen-depleted medium for 24 hr. Cells were then treated with or without 1 nM mibolerone (Mib) for 24 hr followed
by WB. The density of AR was determined by normalizing to ERK2 first and then to the normalized value in mock-treated cells.
(F) Androgens attenuate SPOP-induced polyubiquitination of AR. 293T cells were transfected with the indicated plasmids (4 mg pCMV5-AR, 0, 2, or 4 mg Myc-
SPOP) and treated with or without 1 nM mibolerone for 24 hr followed by treatment with MG132 for 8 hr, IP, and WB.SPOPWT, none of the mutants binds to AR (Figures 5A and 5B).
Accordingly, all the mutants failed to affect the steady-state
levels of endogenous AR in C4-2 cells (Figure 5C). None of the
prostate-cancer-associated mutants were able to promote AR
polyubiquitination (Figure 5D). Finally, we examined the effect
of SPOP mutations on AR protein turnover using S119N and
F133V mutants as two representatives (Barbieri et al., 2012).
Similar to the enzymatic dead mutant SPOP-DBTB (positive
control), S119N and F133V failed to accelerate AR protein turn-
over in comparison to SPOPWT (Figures 5E and 5F). These data
suggest that prostate-cancer-associated mutations of SPOP
abrogate its ability to bind and promote ubiquitination and
degradation of AR.
Androgens Attenuate SPOP-Mediated AR Degradation
It has been known that androgens increase AR protein levels,
whereas they decrease AR mRNA expression (Krongrad et al.,
1991; Kumar et al., 1994). However, the molecular mechanism
by which androgens upregulate AR protein is not fully under-(E and F) Prostate-cancer-associated mutants of SPOP have little or no effect on
vector (CV), wild-type, or mutated SPOP. After 24 hr, cells were treated with 50 m
WB (E). At each time point, the intensity of AR was normalized to the intensity of
obtained in two independent experiments.
Cstood. To determine whether SPOP plays a role in this process,
we examined whether androgen treatment affects SPOP-AR
interaction. As shown in Figure 6A, treatment of C4-2 cells with
mibolerone, a synthetic androgen, largely diminished the inter-
action between endogenous AR and SPOP. This was completely
reversed by treatment with the antiandrogen enzalutamide (Fig-
ure 6A). It is not surprising that enzalutamide treatment alone did
not affect the AR-SPOP interaction because cells were cultured
in androgen-depleted medium (Figure 6A). We further demon-
strated that wild-type SPOP-induced downregulation of AR pro-
tein was largely inhibited by mibolerone, but markedly enhanced
by enzalutamide in C4-2 cells cultured in regular (androgen-
containing) medium (Figure 6B). In contrast, enzalutamide failed
to enhance AR downregulation in C4-2 cells expressing the
prostate-cancer-associated SPOP mutant F133V (Figure 6B).
To further assess the effect of enzalutamide on AR degradation,
we pretreated 22Rv1 cells with cycloheximide to block protein
synthesis. Under this condition, we found that enzalutamide
induced downregulation of full-length AR protein but not ARprotein turnover of endogenous AR. LNCaP cells were transfected with control
g/ml cycloheximide (CHX), and at various time points cells were harvested for
ERK2 first and then to the value at the 0 hr time point (F). A similar result was
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Figure 7. Models Depicting SPOP-Mediated Degradation of AR in
Physiological and Pathological Conditions in Prostate Cancer
(A) Unmutated SPOP promotes degradation of full-length wild-type AR
(AR-WT).
(B) Prostate-cancer-associated SPOP mutants lose the capacity to promote
AR degradation.
(C) Prostate-cancer-derived hinge domain-deficient AR splice variants escape
from SPOP-mediated degradation.
(D) Androgens attenuate SPOP-mediated degradation of AR, whereas the
antiandrogen enzalutamide accelerates this process.variants in a dose-dependent manner (Figure 6C). Furthermore,
we demonstrated that knockdown of endogenous SPOP largely
diminished androgen-induced upregulation of endogenous AR
protein in LNCaP cells (Figure 6D). Next, we examined whether
the androgenic effect on SPOP regulation of AR degradation is666 Cell Reports 6, 657–669, February 27, 2014 ª2014 The Authorsmediated through the degron motif 645ASSTT649. As shown in
Figure 6E, mibolerone treatment significantly increased the pro-
tein level of wild-type AR in 293T cells, but this effect was largely
diminishedwith theDASSTTmutant, which cannot bind to SPOP
(Figure 3B). Finally, we demonstrated that androgen treatment
decreased SPOP-mediated polyubiquitination of wild-type AR
(Figure 6F). These data suggest that SPOP plays a critical role
in androgen-induced stabilization, and antiandrogen-induced
destabilization, of AR in prostate cancer cells.
DISCUSSION
A large-scale somatic mutation study demonstrated that in
approximately 450 tumors, comprising breast, lung, ovarian,
pancreatic, and prostate cancer, the SPOP gene was highly
mutated in prostate cancer (Kan et al., 2010). Recurrent SPOP
mutations in prostate cancer have been confirmed by three inde-
pendent genome-wide studies (Barbieri et al., 2012; Berger
et al., 2011; Grasso et al., 2012). However, the pathophysiology
of prevalent SPOPmutations in prostate cancer is poorly under-
stood. In the present study, we provide evidence that all of the
known prostate-cancer-associated mutants of SPOP lose their
ability to bind to and promote AR ubiquitination and proteasome
degradation. Reciprocally, all the hinge domain null AR splice
variants escape SPOP-mediated degradation. We also provide
evidence that androgens attenuate, whereas antiandrogens
potentiate, SPOP-mediated degradation of AR. Thus, our study
not only identifies AR as a bona fide ubiquitination and degrada-
tion substrate of SPOP, but also demonstrates that the effect of
SPOP on AR degradation is subjected to regulation by physio-
logical and pathological conditions in prostate cancer cells,
including SPOP mutation, AR splicing, exposure to androgen,
and antiandrogen treatment (Figure 7). It is worth noting that
the TMPRSS2-ETS fusion genes, commonly detected in approx-
imately 50%human prostate cancers, are positively regulated by
AR (Kumar-Sinha et al., 2008; Tomlins et al., 2005). Intriguingly,
SPOP mutations (function to stabilize AR) and TMPRSS2-ETS
translocations are mutually exclusive in prostate cancer (Barbieri
et al., 2012). A plausible explanation is that mutations in SPOP
may reverse wild-type SPOP-mediated degradation of protein(s)
that enable to inhibit TMPRSS2-ETS fusion formation, ETS activ-
ity, or both. Further investigation of this concept is warranted.
Activity and abundance of AR protein are crucial for prostate
cancer cell proliferation, tumor progression, and development
of resistance to antiandrogen therapies (Chen et al., 2004). AR
protein levels and functions are subjected to regulation by
various posttranslational modifications including phosphoryla-
tion, acetylation, methylation, SUMOylation, and ubiquitination
(van der Steen et al., 2013). Several E3 ubiquitin ligases,
including MDM2, CHIP, RNF6, and SIAH2, have been found to
bind to AR and play important roles in either promoting AR
degradation or activating AR under various cellular conditions
(He et al., 2004; Lin et al., 2002; Qi et al., 2013; Xu et al., 2009).
Our identification of SPOP as a bona fide E3 ligase of the AR is
highly relevant to prostate cancer, because SPOP-mediated
degradation of AR protein is disrupted by its mutations identified
in prostate cancer, as well as the majority of prostate cancer-
derived AR splicing variants.
SPOP substrates have a consensus motif F-p-S-S/T-S/T
(F, nonpolar; p, polar) that mediates SPOP binding (Zhuang
et al., 2009). This motif is invariably present in SPOP degradation
targets, including the phosphatase Puc (Liu et al., 2009), the tran-
scription regulators Ci/Gli and Daxx (Kwon et al., 2006; Zhang
et al., 2006), and the chromatin component MacroH2A (Herna´n-
dez-Mun˜oz et al., 2005). Through motif analysis, we identified a
perfectly matched SPOP-binding motif (645ASSTT649) in AR.
Deletion of the 645ASSTT649motif completely abolished the inter-
action between SPOP and AR, as well as SPOP-mediated poly-
ubiquitination of AR. Thus, like other canonical SPOP substrates,
AR contains a functional SPOP-binding consensus motif.
SRC-3, a coactivator of AR that is often upregulated in prostate
cancer (Zhou et al., 2005), is another SPOP ubiquitination target
(Geng et al., 2013; Li et al., 2011). A similar sequence is present in
SRC-3 upon phosphorylation at serine 102 by casein kinase IE (Li
et al., 2011). Importantly, prostate-cancer-associatedmutants of
SPOP lose the capability to degrade SRC-3 (Geng et al., 2013).
Thus, it is possible that SPOP mutations augment AR functions
in prostate cancer by inhibiting turnover of both AR and its coac-
tivator SRC-3.
A number of AR splice variants have been identified (Dehm
and Tindall, 2011). Increasing evidence suggests that expression
of AR variants is upregulated during castration-resistant pro-
gression of prostate cancer and that increased expression of
AR variants may contribute to resistance to antiandrogen thera-
pies (Ho¨rnberg et al., 2011; Hu et al., 2012; Li et al., 2013; Sun
et al., 2010; Watson et al., 2010). In agreement with our finding
that the SPOP-binding motif 645ASSTT649 is located in the hinge
domain of the AR, we demonstrated that none of the hinge
domain null AR variants could be bound by SPOP, thereby
escaping SPOP-mediated protein degradation in prostate can-
cer cells. In contrast, we showed that the v567es variant (also
known as AR-V12), in which the hinge domain remains, can be
bound and degraded by SPOP. Because the majority of the AR
variants identified thus far do not harbor the hinge domain
(Dehm and Tindall, 2011), AR splicing represents a key mecha-
nism by which the AR protein escapes SPOP-mediated
polyubiquitination and proteasome degradation, thereby con-
tributing to prostate cancer pathogenesis. Expression of AR
v567es variant increases the stability of full-length AR protein
without increasing mRNA levels in LNCaP cells (Sun et al.,
2010). Thus, it is worthwhile to investigate in the future whether
full-length AR and splicing variants can also be differentially tar-
geted by other E3 ubiquitin ligases for degradation. Moreover,
we provide evidence that the antiandrogen enzalutamide en-
hances degradation of full-length AR but has no effect on AR
variants in 22Rv1 cells. Thus, escaping of AR variants from
SPOP-mediated proteolysis may represent an important mech-
anism that confers resistance to antiandrogen therapy.
Another important finding of our study is that androgen atten-
uates SPOP binding and degradation of AR, whereas enzaluta-
mide promotes this process. Such a dynamic regulation of the
AR thus identifies a paradigm for drug design. Enzalutamide is
an antiandrogen that inhibits the transcriptional activity of AR
by competitively blocking the binding of androgens to AR.
Intriguingly, we found that this drug induces AR degradation by
facilitating SPOP-AR interaction. One possible explanation forCthis is that, when androgens bind to AR, AR undergoes a confor-
mation change, thereby affecting the binding of the 645ASSTT649
motif to SPOP and subsequent AR degradation. In contrast,
when enzalutamide binds to the AR LBD domain, it blocks
androgen binding and thereby facilitates SPOP-AR interaction
andARdegradation. Such aconceptmay lead to novel strategies
for developing drugs that can alter AR conformation, thus facili-
tating E3 ligase-mediated destruction of AR in prostate cancer.
In summary, we have identified AR as a substrate of SPOP. AR
harbors a functional SPOP-binding consensus motif in the hinge
domain. We demonstrated that SPOP promotes AR degradation
and inhibits the transcriptional activity of the AR and AR-medi-
ated prostate cancer proliferation. In contrast, the majority of
AR variants can escape SPOP-mediated destruction due to their
lacking of the hinge domain. Moreover, all SPOPmutations iden-
tified in humanprostate cancers disrupt theSPOP-AR interaction
and abolish SPOP-induced AR degradation. Additionally, we
showed that the antiandrogen enzalutamide enhances SPOP-
mediated degradation of full-length AR, but not most AR variants
in prostate cancer cells. Given the importance of AR in prostate
cancer initiation, progression, and therapy resistance, identifica-
tion of AR as a substrate of SPOP E3 ligase provides a plausible
explanation for the high frequency of SPOPmutations in prostate
cancer. These findings also support a tumor-suppressor function
of SPOP in prostate cancer and emphasize the importance of
this pathway in development of resistance to antiandrogen ther-
apy of prostate cancer in the clinic.
EXPERIMENTAL PROCEDURES
For further details, see the Supplemental Experimental Procedures.
Plasmids and Reagents
The mammalian expression vectors for HA-tagged ubiquitin (HA-Ub), wild-
type AR (AR-WT), and AR variants V2, V4, V5, and V7 were described previ-
ously (Bohrer et al., 2013; Huang et al., 2005; Liu et al., 2008). The AR variant
v567es was kindly provided by Dr. Donald Tindall at Mayo Clinic. HA-SPOP
and Myc-SPOP were cloned into pCMV vector. AR mutants S646A, S647A,
T648A, and T649A and prostate-cancer-associated mutants of SPOP were
generated by site-specific mutagenesis (Stratagene). AR deletion mutants
DEGSSS, DASSTT, 2D, and Myc-SPOP-DBTB were generated by KOD-Plus
Mutagenesis Kit (Toyobo). Antibodies used were anti-AR (N20), anti-ERK2,
anti-Myc tag (Santa Cruz Biotechnology), anti-SPOP (Abcam), and anti-HA
(Covance). MG132, cycloheximide, and mibolerone were purchased from
Sigma-Aldrich. The antiandrogen enzalutamide was kindly provided by
Medivation.
Immunoprecipitation and Western Blotting
Immunoprecipitations were performed as described previously (Huang et al.,
2006; Wang et al., 2013). For western blotting, protein samples were prepared
in modified RIPA buffer (13 PBS, 1% NP-40, 0.1% SDS, and 1% protease in-
hibitor cocktails). Equal amounts of protein (50–100 mg) from cell lysates were
denatured and subjected to SDS-PAGE and were transferred to nitrocellulose
membranes (Bio-Rad). The membranes were immunoblotted with specific
primary antibodies and horseradish-peroxidase-conjugated secondary anti-
bodies and visualized by SuperSignal West Pico Stable Peroxide Solution
(Thermo Scientific).
Statistical Analysis
Experiments were carried out with three or more replicates unless otherwise
stated. Statistical analyses were performed by Student’s t test for most
studies. Values with p < 0.05 are considered statistically significant.ell Reports 6, 657–669, February 27, 2014 ª2014 The Authors 667
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